ResourceLife Sciences
Using SPARCL technology to Develop Immunoassays for Biomarker Detection and Pharmacokinetic Studies
Using SPARCL technology to Develop Immunoassays for Biomarker Detection and Pharmacokinetic Studies
25 Aug 2015This application note demonstrates how the performance of the FLUOstar Omega microplate reader enables the detection of SPARCL (Spatial Proximity Analyte Reagent Capture Luminescence) assays. Examples of biomarker detection and pharmacokinetic assays are presented. SPARCL detection technology was used for rapid immunoassay development. This technology is a proximity dependent and homogeneous method where an antibody/antigen interaction leads to proximity of a chemiluminescent substrate and an oxidative enzyme.